While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

These branded prescription pharmaceuticals – approved by the Food and Drug Administration – are so popular and in demand that pharmaceutical manufacturers could not keep up with production.

Eli Lilly has emerged as a popular growth stock thanks to its strength in the weight loss space ... Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to ...

Despite instructions of closure by federal authorities tomorrow, many compounded versions of weight-loss drugs are available ...

Let's dig into what Lilly's business looks like beyond weight loss treatments ... Mounjaro is Lilly's largest source of revenue while Zepbound is the company's fastest-growing business ...

The agency did the same for Lilly’s tirzepatide, found in its obesity and diabetes meds Zepbound and Mounjaro ... impact on the market for weight loss drugs. As many as 1 in 8 U.S. adults ...

Novo pioneered the use of drugs stimulating a gut hormone called GLP-1 to help people with obesity lose weight. Lilly showed that, by acting on a second one called GIP, Zepbound could improve GLP ...

According to Truist, Eli Lilly maintains a leadership position with Zepbound’s strong sales performance and a commitment to invest more than $50 billion in manufacturing and ... targeting myostatin ...

A United States Senator has disclosed a series of stock trades, some raising questions about possible insider information use ...